Orion Portfolio Solutions LLC Has $3.16 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Orion Portfolio Solutions LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,103 shares of the medical research company’s stock after selling 216 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in IQVIA were worth $3,164,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Synergy Asset Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at $33,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA during the 4th quarter valued at $44,000. Zions Bancorporation N.A. lifted its stake in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Versant Capital Management Inc increased its position in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after buying an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in IQVIA during the fourth quarter valued at about $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the subject of several analyst reports. Stephens assumed coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Morgan Stanley upped their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Robert W. Baird dropped their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, January 21st. Truist Financial restated a “buy” rating and set a $263.00 price target (up from $261.00) on shares of IQVIA in a report on Monday, February 10th. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Stock Down 0.6 %

Shares of IQV opened at $176.28 on Tuesday. IQVIA Holdings Inc. has a 12 month low of $169.37 and a 12 month high of $253.84. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50-day moving average price of $192.73 and a two-hundred day moving average price of $205.61. The stock has a market cap of $31.08 billion, a price-to-earnings ratio of 23.50, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.